Teladoc Health Delivers Mixed Results, 'Sobering' Guidance: 6 Analysts Provide Key Takeaways
Datadog's Q3 Earnings Success Sparks Analyst Optimism, Hints At Bullish Tech Market Recovery
3 Lucid Group Analysts Unpack Disappointing Q3 Print: 'No New Products' To Boost Margins
Generac's Outlook Brightens On Q3 Earnings: Analyst Upgrades Stock On 'Attractive Current Valuation'
Guggenheim Securities Recent News
Fortinet Must Face 'Reality Of Constrained Demand' After Mixed Q3, Analyst Says
Meta Platforms Reports Solid Q3 Print, But Q4 Outlook Is A Concern: 7 Analysts Dive Deeper Into Results
Is Splunk A Good Investment After Cisco Deal Announcement? 7 Analysts Weigh In
5 Lululemon Analysts Praise Apparel Maker's Q2 Print, Outlook: 'Momentum Across The Board'
Palo Alto Networks Stock Shoots Up After Q4 Print: 5 Analysts Deep Dive Into Why, Outlook
Oracle Exhibits Strong And Sustained Cloud Momentum: 5 Wall Street Analysts React To FQ4 Results
Will CrowdStrike Have A Weak Q2? 4 Analysts On 'Solid' Q1 Print, Macro Pressures
Chewy Inc's Shares Surge As Q1 Earnings Exceed Expectations: 4 Analysts Applaud Results
Rain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their Views
7 Lululemon Athletica Analysts On Q4 Print: 'Demand For LULU's Merchandise Remains Healthy And Strong,' But There May Be A Headwind
7 CrowdStrike Holdings Analysts Dissect The 'Solid' Beat And Raise Quarter
Why 5 Target Analysts Are Maintaining Ratings Following Q4 Results
These 6 Palo Alto Networks Analysts Are Happy With FQ2 Print
Why These 4 Pinterest Analysts Are Happy With Q4 Results
Tesla's Pricing Power Will Suffer Due To New IRS Rules For EV Sales Credit, Analyst Says
Oracle Faces Uncertain Macro Outlook In 2023, 3 Analysts' Takeaways On FQ2 Print
Beauty Is Pain To The Pocketbook: Ulta Posts Q3 Earnings Beat, Raises Prices And Outlook
8 Zscaler Analysts Offer Their Takes On Q3 Print: Why The Company May 'Need To Tread Carefully Throughout FY23'
Why These 3 Foot Locker Analysts Are More Excited About New CEO Than Q2 Results
Square's Recent Weakness Is An Investor's Chance To Buy Stock, Says Analyst
Amneal Analyst: Pharma Well-Positioned Ahead Of 2021 Generic Launches
Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk
Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation